Related Experiment Video
Updated: Jun 15, 2026

Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
Decline in rejection in the first year after pediatric cardiac transplantation: a multi-institutional study
Jeffrey G Gossett1, Charles E Canter, Jie Zheng
1Department of Pediatrics, Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. JGossett@Childrensmemorial.org
Insights
Pediatric heart transplant rejection incidence decreased significantly over time. However, rejection episodes causing hemodynamic compromise or death remain unchanged, highlighting areas for continued research in pediatric heart transplantation outcomes.
Area of Science:
- Pediatric Cardiology
- Transplantation Immunology
- Immunosuppression Therapy
Background:
- Graft rejection is a primary cause of morbidity and mortality in pediatric heart transplantation (HTx).
- While survival rates have improved, the trend in allograft rejection occurrence over time remains unclear.
Purpose of the Study:
- To determine the incidence of rejection in pediatric heart transplant recipients.
- To identify factors associated with the first rejection episode within the first year post-transplant.
Main Methods:
- Analysis of the Pediatric Heart Transplant Study (PHTS) database.
- Inclusion of patients who underwent HTx between January 1993 and December 2005.
- Multivariate analysis to identify risk factors for rejection.
Main Results:
- Rejection incidence declined from approximately 60% to 40% between 1993 and 2005.
- The mean number of rejection episodes per patient/year significantly decreased.
- Rejection with hemodynamic compromise or death from rejection did not change; later transplant year and mechanical support reduced rejection risk, while positive crossmatch and older recipient age increased it.
Conclusions:
- The overall incidence and prevalence of rejection have substantially decreased in pediatric HTx recipients within the first year post-transplant.
- Rates of rejection leading to hemodynamic compromise or death remain unchanged.
- Further research is needed to address severe rejection outcomes.
Background:
Rejection is a major cause of morbidity and mortality after pediatric heart transplantation (HTx). Survival after pediatric HTx has improved over time, but whether there has been an era-related improvement in the occurrence of allograft rejection is unknown.
Methods:
The Pediatric Heart Transplant Study (PHTS) database was queried for patients who underwent HTx from January 1993 to December 2005 to determine the incidence of rejection and identify factors associated with the first episode of rejection in the first year after HTx.
Results:
Data were reviewed in 1,852 patients from 36 centers. The incidence of rejection declined over 13 years at a rate of -2.58 +/- 0.41 (p < 0.001) from approximately 60% to 40% (p < 0.001). The mean number of episodes of rejection also significantly fell at a rate of -0.05 +/- 0.01 per patient/year from 1.19 to 0.66 (p < 0.001). The incidence of rejection with hemodynamic compromise and death from rejection did not change. Multivariate analysis for the risk of a first rejection episode demonstrated decreased risk of rejection with later year of HTx (odds ratio [OR], 0.88; 95% confidence interval [CI], 0.85-0.91; p < 0.001) and use of mechanical support (OR, 0.65; 95% CI, 0.42-0.99; p = 0.046). Increased risk of rejection was associated with positive donor-specific crossmatch (OR, 1.85; 95% CI, 1.18-2.88; p = 0.007) and older recipient age (OR, 1.05; 95% CI, 1.02-1.07; p < 0.001).
Conclusions:
Although the overall incidence and prevalence of rejection has substantially decreased over time in pediatric HTx recipients in the first year after HTx, the rate of rejection with hemodynamic compromise or death from rejection remains unchanged.
More Related Videos
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Kidney Transplant III: Nursing Management
